Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, commonly known as Sobi, is a leading biopharmaceutical company headquartered in Sweden (SE). Founded in 1991, Sobi has established itself as a key player in the biotechnology industry, focusing on rare diseases and specialty care. With a strong operational presence across Europe, North America, and the Asia-Pacific region, Sobi is dedicated to developing innovative therapies that address unmet medical needs. Sobi's core product portfolio includes treatments for haemophilia, inflammation, and genetic disorders, distinguished by their commitment to patient-centric solutions and advanced biopharmaceutical technologies. The company has achieved significant milestones, including strategic partnerships and a robust pipeline of therapies, solidifying its market position as a trusted provider in the rare disease sector. Sobi continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by complex health conditions.
DitchCarbon Score
How does Swedish Orphan Biovitrum's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Swedish Orphan Biovitrum's score of 35 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Swedish Orphan Biovitrum's reported carbon emissions
In 2023, Swedish Orphan Biovitrum (Sobi) reported total carbon emissions of approximately 124,565,000 kg CO2e. This figure includes 904,000 kg CO2e from Scope 1 emissions, primarily from mobile combustion, and 648,000 kg CO2e from Scope 2 emissions, mainly from purchased electricity. The company’s Scope 3 emissions were significantly higher, at about 124,565,000 kg CO2e, with business travel contributing 9,895,000 kg CO2e. In 2022, Sobi's total emissions were approximately 112,957,000 kg CO2e, with Scope 1 emissions at 787,000 kg CO2e and Scope 2 emissions at 563,000 kg CO2e. The Scope 3 emissions for that year were also substantial, reflecting the company's extensive supply chain and operational activities. Sobi has not publicly committed to specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. However, the company continues to monitor and report its emissions across all three scopes, demonstrating a commitment to transparency in its environmental impact. Overall, Sobi's emissions data highlights the significant challenges faced by the biopharmaceutical industry in reducing carbon footprints, particularly in Scope 3 emissions, which often represent the largest share of total emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 435,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 1,157,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 1,031,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Swedish Orphan Biovitrum is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
